MC2 Biotek

MC2 Biotek is a Danish biotechnology holding company established in 2006. Its structure brings together three specialist biotechnology businesses: DrugMode, based in Denmark; Zadec, also based in Denmark; and Drug Delivery Solutions Limited, based in the United Kingdom. Rather than presenting a single consumer-facing product line, MC2 Biotek operates as a platform for several complementary research and development activities in pharmaceutical technology and biomedical science. DrugMode is associated with three-dimensional cell-culture technology and is based at the University of Southern Denmark in Odense. Its work includes the ProtoTissue bioreactor, a system designed to support the growth of cells from an immortal human hepatocyte line into three-dimensional spheroids. Three-dimensional cultures are intended to reproduce aspects of living tissue more realistically than conventional two-dimensional cultures, making them potentially useful for evaluating drug metabolism and toxicology during preclinical development. Zadec focuses on diabetes and nutrition. Its reported research portfolio includes RX-1, an oral anti-diabetes drug described as being in clinical trials, as well as research into the possible anti-diabetic and anti-obesity properties of rooibos and honeybush teas. MC2 Biotek has collaborated with South African researchers connected with the Medical Research Council and Agricultural Research Council on this area. Experimental work cited in reference material reported that a hot-water honeybush extract improved blood-glucose regulation and other diabetes-related indicators in rat models of type 2 diabetes. These findings represent research-stage evidence rather than confirmation of a marketed human therapy. Drug Delivery Solutions develops formulation and delivery technologies for dermatology and ophthalmology. Its reported platform is polyaphron dispersion, or PAD, a biliquid foam technology in which oil or multiphase liquid droplets are dispersed within an aqueous or other hydrogen-bonding liquid phase. The formulation can accommodate oil-soluble drug molecules and may be adjusted to influence release characteristics. Reported applications include topical medicines, including a cream for psoriasis, and formulations intended for wound-dressing or extended-release use. MC2 Biotek’s overall positioning is therefore centered on applied biotechnology: translating laboratory concepts into drug-delivery systems, disease-focused therapies, nutrition research, and experimental models for pharmaceutical testing. Its work spans Denmark and the United Kingdom, with research links extending internationally through the South African tea studies. Publicly available reference material does not establish a current executive roster, ownership structure, listed status, commercial revenue, or a definitive present operating status. It also does not provide enough information to determine the current clinical, regulatory, or market status of the reported products and technologies.

MC2 Biotek was established in 2006 in Denmark as a biotechnology holding company. Its reported organization consists of three smaller businesses with distinct technical specialties: DrugMode, Zadec, and Drug Delivery Solutions Limited. This structure enabled MC2 Biotek to address several stages and methods of pharmaceutical research rather than concentrate on one therapeutic area. DrugMode developed work in three-dimensional cell culture and was associated with the University of Southern Denmark in Odense. One of its reported technologies is the 3D ProtoTissue Bioreactor, which supports the formation of three-dimensional spheroids from cells derived from an immortal human hepatocyte line. The rationale for this approach is that three-dimensional cultures can more closely reflect aspects of tissue behavior in the body than standard two-dimensional cultures. Such models may therefore be used in drug-metabolism and toxicology studies, although the available reference material does not establish the extent of adoption or current commercial availability. Zadec concentrated on diabetes and nutrition. Its portfolio included RX-1, described in the available material as an oral anti-diabetes drug candidate undergoing clinical trials. The reference material does not identify the trial phase, sponsor details, clinical results, regulatory status, or subsequent development outcome. Zadec’s research also included plant-based nutritional studies. MC2 Biotek collaborated with South African researchers led by Johan Louw at the Medical Research Council and Lizette Joubert at the Agricultural Research Council to investigate rooibos and honeybush teas for possible anti-diabetic and anti-obesity effects. In one reported animal study, an aqueous hot-water honeybush extract was administered to type 2 diabetes rat models and was associated with improved glucose regulation and other disease-related measures. These results were preclinical and do not by themselves demonstrate efficacy or approval in humans. Drug Delivery Solutions Limited, described as the Leatherhead, United Kingdom-based subsidiary of MC2 Biotek, developed a formulation and delivery method known as polyaphron dispersions, or PAD. The technology uses a complex internal phase in a biliquid foam or emulsion system, with oil or multiphase liquid droplets dispersed in water or another hydrogen-bonding liquid. Oil-soluble active ingredients can be placed in the oil phase, while the composition of the phases can be modified to influence drug release and administration characteristics. A patent associated with the technology in 2008 described formulations with a high dispersed-oil content and a relatively low surfactant level. Reported potential uses included extended-release enteral delivery and wound-dressing formulations. The PAD platform was also applied to dermatology and ophthalmology. Reported development work included topical medicines such as a cream intended for psoriasis. The available material characterizes these technologies as commercially applied in those fields, but it does not provide product names, sales figures, regulatory approvals, licensing arrangements, or current availability. Overall, MC2 Biotek’s documented history is that of a small, research-oriented biotechnology group linking therapeutic candidates, formulation science, nutrition research, and laboratory models. Public sources supplied for this dossier do not document later corporate developments, acquisitions, changes in ownership, current leadership, financial performance, or a verified current operating status.

• 2008

  PAD drug-delivery patent described

  [1]MC2 Bioteken.wikipedia.org

  A patent associated with Drug Delivery Solutions described polyaphron dispersion formulations for controlled or extended drug delivery and possible wound-dressing applications.

• 2006

  MC2 Biotek established

  [1]MC2 Bioteken.wikipedia.org

  MC2 Biotek was established in Denmark as a biotechnology holding company bringing together specialist businesses in drug delivery, diabetes and nutrition, and three-dimensional cell culture.

Applied biotechnology platform combining pharmaceutical formulation, drug delivery, disease-focused therapeutic research, nutrition science, and three-dimensional in-vitro testing models.

• In-vitro research equipment

  3D ProtoTissue Bioreactor

  The 3D ProtoTissue Bioreactor is a reported DrugMode technology for growing cells from an immortal human hepatocyte line into three-dimensional spheroids. The system is intended to provide an in-vitro tissue model that is more representative of aspects of in-vivo biology than conventional two-dimensional cell cultures. Its proposed uses include drug-metabolism and toxicology testing during pharmaceutical research. The available source does not establish current sales, regulatory classification, or the extent of external adoption.

• Oral anti-diabetes drug candidate

  RX-1

  RX-1 is an oral anti-diabetes drug candidate associated with Zadec. Reference material describes it as being in clinical trials, but does not specify the trial phase, mechanism of action, clinical findings, regulatory pathway, or whether development continued. It should therefore be treated as a development-stage candidate rather than a confirmed marketed medicine.

• Drug-delivery formulation technology

  Polyaphron Dispersions

  Polyaphron dispersions, or PAD, are biliquid-foam formulations in which oil or multiphase liquid droplets are dispersed within an aqueous or other hydrogen-bonding liquid phase. Oil-soluble drug molecules can be incorporated into the internal oil phase, while the formulation components can be varied to influence release and administration. Reported applications include extended-release enteral delivery, wound dressings, and topical dermatology and ophthalmology products.

• Dermatology drug formulation

  Psoriasis topical cream

  Drug Delivery Solutions was reported to have developed a topical cream for psoriasis using its drug-formulation and delivery technology. The source material does not give the product name, active ingredient, approval status, commercialization details, or current availability.

1. 1MC2 Bioteken.wikipedia.org